Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 vs AZD1222 Phase 3 Immunobridging Study
NCT05011526Phase 3Completed
- Sponsor
- Medigen Biotechnology
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MVC-COV1901 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medigen Biotechnology. Primary endpoints: Immunogenicity of neutralizing antibody (GMT ratio) at Day 43 and Incidence of Adverse Event. Started Oct 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05011526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011526.